Intas and Axantia signed an agreement to commercialise Ranibizumab in the Middle East

subsidiaries; Pharma International Pharmaceutical & Chemical Manufacturing Co Ltd and Med City Pharmaceutical Productions for Ranibizumab (biosimilar of Lucentis).

Under the terms of this settlement, Axantia will register, hold the marketing authorisation and commercialise Ranibizumab in certain territories including Saudi Arabia, Jordan, Iraq, Lebanon and GCC countries. Intas has developed a biosimilar of Lucentis, which is currently under Phase III global trial for submission in major countries including EMA & the US.